IRADIMED Community

NasdaqGM:IRMD Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility

Key Takeaways Focus on the 3870 MR IV pump is expected to drive long-term revenue growth, with expanded sales and market penetration enhancing future earnings. New facility and increased infrastructure investments aim to boost capacity and efficiency, supporting stable margins and long-term revenue growth despite initial expenses.

US$71.00

FV

27.1% undervalued

12.77%

Revenue growth p.a.

0

0

2

4 days ago